Table 3.
Cox Proportional Hazard Analyses.
| Covariate | P- value | HR (95% CI) |
|---|---|---|
| Univariate Analyses* | ||
| Clinicopathological Variables | ||
| HER2 | 0.7816 | 1.18 (0.36 - 3.84) |
| PgR | 0.5147 | 0.78 (0.36 - 1.66) |
| Histological grade | 0.0032 | 1.99 (1.26 - 3.14) |
| Ki-67 LI | 0.0226 | 1.02 (1.00 - 1.04) |
| Tumor size | 0.0047 | 1.22 (1.06 - 1.39) |
| Number of positive nodes | <0.0001 | 1.13 (1.08 - 1.18) |
| Treatment (4 categories) | 0.1540 | - |
| Molecular scores | ||
| HER2_2 | 0.1080 | 1.20 (0.96 - 1.51) |
| PGR_5 | 0.0344 | 0.66 (0.44 - 0.97) |
| PRO_5 | 0.0003 | 2.14 (1.42 - 3.22) |
| PRO_10 | <0.0001 | 2.09 (1.45 - 3.00) |
| RISK_25 | 0.0001 | 1.54 (1.24 - 1.91) |
| Multivariate Analyses: Comparison of PRO_10 and Ki-67 LI** | ||
| Model 1: log-likelihood = -179.38, Deviance = 188.11 | ||
| Number of positive nodes | <0.0001 | 1.19 (1.12 - 1.27) |
| Tumor size | 0.0370 | 1.19 (1.01 - 1.39) |
| Grade | 0.4200 | 1.25 (0.72 - 2.17) |
| Ki-67 LI | 0.1300 | 1.02 (1.00 - 1.04) |
| Model 2: log-likelihood = -175.75, Deviance = 180.71 | ||
| Number of positive nodes | <0.0001 | 1.19 (1.12 - 1.27) |
| Tumor size | 0.1300 | 1.14 (0.96 - 1.34) |
| Grade | 0.9600 | 0.99 (0.55 - 1.76) |
| PRO_10 | 0.0092 | 2.12 (1.20 - 3.72) |
| Ki-67 LI | 0.8100 | 1.00 (0.97 - 1.03) |
| Model 3: log-likelihood = -175.78, Deviance = 180.77 | ||
| Number of positive nodes | <0.0001 | 1.19 (1.12 - 1.27) |
| Tumor size | 0.1200 | 1.14 (0.97 - 1.34) |
| Grade | 0.9400 | 0.98 (0.55 - 1.74) |
| PRO_10 | 0.0026 | 2.03 (1.28 - 3.23) |
| Multivariate Analyses: Role of PGR_5*** | ||
| Model 4: log-likelihood = -215.27, Deviance = 214.30 | ||
| Number of positive nodes | <0.0001 | 1.12 (1.07 - 1.16) |
| Tumor size | 0.2000 | 1.11 (0.95 - 1.30) |
| Grade | 0.0170 | 1.78 (1.11 - 2.87) |
| PGR_5 | 0.0570 | 0.68 (0.45 - 1.01) |
| Model 5: log-likelihood = -211.85, Deviance = 208.03 | ||
| Number of positive nodes | <0.0001 | 1.06 (1.06 - 1.16) |
| Tumor size | 0.4300 | 1.07 (0.91 - 1.26) |
| Grade | 0.3000 | 1.32 (0.78 - 2.23) |
| PRO_10 | 0.0092 | 1.73 (1.15 - 2.62) |
| PGR_5 | 0.0360 | 0.65 (0.43 - 0.97) |
| Model 6: log-likelihood = -214.10, Deviance = 211.25 | ||
| Number of positive nodes | <0.0001 | 1.11 (1.06 - 1.16) |
| Tumor size | 0.1700 | 1.13 (0.95 - 1.34) |
| Grade | 0.2100 | 1.40 (0.83 - 2.37) |
| PRO_10 | 0.0150 | 1.71 (1.11 - 2.62) |
*Histological grading was analyzed according to three categories (histological grade I, II or III). Number of lymph node metastases and tumor size were continuous variables. PgR and Her2 were centrally assessed and binary IHC data were included in the analyses [30,31]. Centrally assessed Ki-67 labeling index and molecular scores were included as continuous variables.
**Data of 299 patients with available Ki-67 LI were included in model 1, 2 and 3, respectively.
***Data of all 342 patients were included in model 4, 5 and 6, respectively.
Abbreviations: HR, hazard ratio; CI, confidence interval; LRT, likelihood ratio test; Ki-67 LI, Ki-67 labeling index.
Models 3 and 6 should not be compared directly as they were fitted on different sample sizes, due to missing data in Ki-67 LI.